HRP20010590A2 - Triazole compounds and their use - Google Patents

Triazole compounds and their use Download PDF

Info

Publication number
HRP20010590A2
HRP20010590A2 HR20010590A HRP20010590A HRP20010590A2 HR P20010590 A2 HRP20010590 A2 HR P20010590A2 HR 20010590 A HR20010590 A HR 20010590A HR P20010590 A HRP20010590 A HR P20010590A HR P20010590 A2 HRP20010590 A2 HR P20010590A2
Authority
HR
Croatia
Prior art keywords
phenyl
alkyl
triazol
propyl
methyl
Prior art date
Application number
HR20010590A
Other languages
English (en)
Croatian (hr)
Inventor
Dorothea Starck
Hans-Joerg Treiber
Liliane Unger
Barbara Neumann-Schultz
Kai Blumbach
Dietmar Schoebel
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of HRP20010590A2 publication Critical patent/HRP20010590A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
HR20010590A 1999-01-12 2001-08-10 Triazole compounds and their use HRP20010590A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19900811 1999-01-12
PCT/EP2000/000177 WO2000042036A1 (de) 1999-01-12 2000-01-12 Triazolverbindungen mit dopamin-d3-rezeptoraffinität

Publications (1)

Publication Number Publication Date
HRP20010590A2 true HRP20010590A2 (en) 2003-08-31

Family

ID=7894006

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010590A HRP20010590A2 (en) 1999-01-12 2001-08-10 Triazole compounds and their use

Country Status (28)

Country Link
US (3) US6579892B1 (ja)
EP (3) EP1140908B1 (ja)
JP (3) JP4615125B2 (ja)
KR (3) KR100687682B1 (ja)
CN (3) CN1149209C (ja)
AR (3) AR022229A1 (ja)
AT (3) ATE449768T1 (ja)
AU (3) AU2289700A (ja)
BG (2) BG65105B1 (ja)
BR (2) BR0007500A (ja)
CA (3) CA2359952A1 (ja)
CO (3) CO5150227A1 (ja)
CZ (2) CZ20012550A3 (ja)
DE (3) DE50014472D1 (ja)
ES (2) ES2288839T3 (ja)
HK (1) HK1045311B (ja)
HR (1) HRP20010590A2 (ja)
HU (2) HUP0200522A3 (ja)
ID (2) ID29930A (ja)
IL (3) IL144137A0 (ja)
NO (2) NO20013443L (ja)
NZ (2) NZ512864A (ja)
PL (2) PL201889B1 (ja)
SK (2) SK9862001A3 (ja)
TR (2) TR200102026T2 (ja)
TW (1) TWI274750B (ja)
WO (3) WO2000042036A1 (ja)
ZA (2) ZA200106585B (ja)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
SK4782001A3 (en) 1998-10-08 2001-11-06 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
AR022229A1 (es) 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
CA2408913A1 (en) * 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
AR035369A1 (es) * 2000-11-14 2004-05-12 Smithkline Beecham Plc Derivados de tetrahidrobenzazepina composiciones farmaceuticas que los comprenden, el uso de dichos derivados en la fabricacion de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
WO2003062205A1 (en) * 2001-12-21 2003-07-31 Smithkline Beecham P.L.C. 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders
US7314937B2 (en) * 2002-03-21 2008-01-01 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses
AR040126A1 (es) 2002-05-29 2005-03-16 Glaxo Group Ltd Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
DE10304870A1 (de) 2003-02-06 2004-08-19 Abbott Gmbh & Co. Kg Triazolverbindungen und ihre therapeutische Verwendung
ES2308157T3 (es) * 2003-03-17 2008-12-01 Bayer Healthcare Ag Disgnosticos y tratamientos para enfermedades asociadas con el receptor de la dopamina d3 (drd3).
US6919342B2 (en) 2003-06-05 2005-07-19 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
US20080207685A1 (en) * 2003-11-20 2008-08-28 Eli Lilly And Company Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar
KR20050054084A (ko) * 2003-12-03 2005-06-10 한국전자통신연구원 수신 환경에 기반한 위성 상태 데이터 분배 기능을 가지는위성관제 시스템 및 그 방법
ES2380990T3 (es) * 2004-02-23 2012-05-22 Glaxo Group Limited Derivados de azabiciclo[3.1.0]hexano útiles como moduladores de los receptores D3 de dopamina
EP1737851A1 (en) * 2004-03-08 2007-01-03 Glaxo Group Limited Tetrahydrobenzazepine derivatives as modulators of dopamine d3 receptors (antipsychotic agents)
US7563905B2 (en) * 2004-03-12 2009-07-21 Wyeth Triazole derivatives and method of using the same to treat HIV infections
GB0412314D0 (en) * 2004-06-02 2004-07-07 Glaxo Group Ltd Compounds
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
GB0413879D0 (en) * 2004-06-21 2004-07-21 Glaxo Group Ltd Compounds
GB0414795D0 (en) * 2004-07-01 2004-08-04 Glaxo Group Ltd Compounds
ATE452134T1 (de) 2004-08-09 2010-01-15 Abbott Gmbh & Co Kg Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen
CA2577060A1 (en) * 2004-08-13 2006-02-23 Amgen Inc. Substituted benzofused heterocycles
CA2588457A1 (en) 2004-12-02 2006-06-08 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
GB0507602D0 (en) 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
DE602006017543D1 (de) * 2005-06-14 2010-11-25 Glaxo Group Ltd Neue verbindungen
EP1928846B1 (en) 2005-08-18 2014-06-04 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2007022933A1 (en) * 2005-08-22 2007-03-01 Glaxo Group Limited Triazole derivatives as modulators of dopamine d3 receptors
WO2007028145A2 (en) * 2005-09-02 2007-03-08 Dara Biosciences, Inc. Agents and methods for reducing protein tyrosine phosphatase 1b activity in the central nervous system
US20070293548A1 (en) * 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
EP2118077B1 (en) 2007-02-08 2014-12-24 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EP2323737A2 (en) 2008-08-08 2011-05-25 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US9227944B2 (en) 2008-10-10 2016-01-05 Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China Dopamine D3 receptor ligands and preparation and medical uses of the same
CN102264733B (zh) 2008-10-10 2014-07-30 中国人民解放军军事医学科学院毒物药物研究所 新型多巴胺d3受体配体，其制备方法及其医药用途
US9326955B2 (en) * 2008-10-31 2016-05-03 Loyola University Chicago Combination pharmaceuticals and methods thereof using proteinacious channels as treatments for medical conditions
CA2785455A1 (en) * 2009-12-22 2011-07-21 Cephalon, Inc. Tricyclic derivatives and their pharmaceutical use and compositions
TW201300358A (zh) * 2011-03-14 2013-01-01 大正製藥股份有限公司 含氮縮合雜環化合物
SG11201406890YA (en) * 2012-05-30 2014-11-27 Hoffmann La Roche Triazolo compounds as pde10 inhibitors
RU2561063C1 (ru) * 2014-07-01 2015-08-20 Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") Способ коррекции неврологических нарушений при хронической алкогольной интоксикации
EP3189041B1 (en) 2014-09-03 2021-04-28 Ctxt Pty Ltd Tetrahydroisoquinoline derived prmt5-inhibitors
US10005792B2 (en) 2014-09-03 2018-06-26 Ctxt Pty. Ltd. Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
GB201604022D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604031D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604030D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604027D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604029D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604020D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
US11136312B2 (en) * 2017-05-12 2021-10-05 Board of Trustees of the Southern Illinois University 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
US10941153B2 (en) * 2018-05-31 2021-03-09 Regents Of The University Of Minnesota Substituted phenethylamine derivatives
GB202117129D0 (en) * 2021-11-26 2022-01-12 Epidarex Exeed Ltd Compounds

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4408049A (en) 1980-09-17 1983-10-04 The Upjohn Company Substituted piperazinyl-1,2,4-triazoles
US4338453A (en) 1980-09-17 1982-07-06 The Upjohn Company Aminoalkyl-1,2,4-triazoles
US4577020A (en) * 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
FR2601952B1 (fr) 1986-07-23 1988-11-25 Carpibem Nouveaux derives amino alkyl thio de triazolopyridine ou triazoloquinoline, leurs procedes de preparation, medicaments les contenant, utiles notamment comme antalgiques
AU644500B2 (en) * 1990-12-20 1993-12-09 Merrell Dow Pharmaceuticals Inc. 3-aryl-5-alkylthio-4h-1,2,4-triazoles for treatment of hyperreflexia due to spinal trauma
AU1928792A (en) 1991-05-20 1992-12-30 Upjohn Company, The Carboxamido-(1,2n)-carbocyclic-2-aminotetralin derivatives
WO1993008799A1 (en) 1991-11-05 1993-05-13 Smithkline Beecham Corporation Endothelin receptor antagonists
FR2687146B1 (fr) 1992-02-12 1994-04-01 Adir Cie Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
KR100331667B1 (ko) 1993-04-27 2002-11-08 스미스클라인 비참 코포레이션 엔도텔린수용체길항제
DE4338396A1 (de) * 1993-11-10 1995-05-11 Basf Ag N-Substituierte Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
FR2722194B1 (fr) 1994-07-06 1996-08-23 Adir Nouveaux derives de benzopyrane, leur procede de preparation et les compositions pharmacuetiques qui les contiennent
DE4425144A1 (de) * 1994-07-15 1996-01-18 Basf Ag Triazolverbindungen und deren Verwendung
AU4368996A (en) * 1994-11-23 1996-06-17 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
DE69608551T2 (de) 1995-03-27 2001-01-18 Smithkline Beecham Plc Bicyclische amin-derivate und ihre verwendung als antipsychotische wirkstoffe
AU5272296A (en) 1995-04-06 1996-10-23 Novo Nordisk A/S Benzopyranopyrrole compounds, their preparation and use
GB9518572D0 (en) 1995-09-12 1995-11-15 Smithkline Beecham Plc Compounds
AU7490496A (en) * 1995-11-10 1997-05-29 Novo Nordisk A/S Enantiomers of cis-benz{e}indole compounds, their preparation and utility as dopamine-d3 receptor selective agents
FR2742149B1 (fr) 1995-12-11 1998-02-13 Inst Nat Sante Rech Med Nouveaux derives de 2-naphtamides et leurs applications therapeutiques
DE19600934A1 (de) * 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
US5688950A (en) 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
ES2191838T3 (es) * 1996-05-11 2003-09-16 Smithkline Beecham Plc Derivados de tetrahidroisoquinoleina como moduladores de los receptores d3 de la dopamina.
WO1997045403A1 (en) * 1996-05-31 1997-12-04 Pharmacia & Upjohn Company Aryl substituted cyclic amines as selective dopamine d3 ligands
GB9612153D0 (en) 1996-06-11 1996-08-14 Smithkline Beecham Plc Compounds
AU4204697A (en) 1996-08-14 1998-03-06 Smithkline Beecham Plc Tetrahydroisoquinoline derivatives and their pharmaceutical use
JPH10195056A (ja) * 1996-11-12 1998-07-28 Takeda Chem Ind Ltd 縮合ベンゼン誘導体、その製造法および剤
CZ194499A3 (cs) 1996-12-06 1999-11-17 Abbott Laboratories Benzopyranopyrolové a benzopyranopyridín alfa-1 adrenergické sloučeniny
FR2760014B1 (fr) * 1997-02-27 1999-04-09 Adir Nouveaux composes de 2-amino indane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9708694D0 (en) * 1997-04-30 1997-06-18 Smithkline Beecham Plc Compounds
GB9708805D0 (en) * 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
JP2002501506A (ja) 1997-05-03 2002-01-15 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ドーパミンｄ▲下３▼受容体のモジュレーターとしてのテトラヒドロイソキノリン誘導体
GB9709303D0 (en) * 1997-05-09 1997-06-25 Smithkline Beecham Plc Compounds
GB9710366D0 (en) * 1997-05-20 1997-07-16 Biocompatibles Ltd Stent deployment device
FR2764890B1 (fr) 1997-06-24 1999-08-27 Adir Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19728996A1 (de) * 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
AR022229A1 (es) 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion

Also Published As

Publication number Publication date
EP1140907B1 (de) 2007-07-11
HUP0200522A3 (en) 2003-05-28
CA2359948C (en) 2010-09-21
ATE424398T1 (de) 2009-03-15
BG105784A (en) 2002-02-28
ATE449768T1 (de) 2009-12-15
EP1140907A1 (de) 2001-10-10
CZ20012551A3 (cs) 2002-03-13
WO2000042036A1 (de) 2000-07-20
KR20070032830A (ko) 2007-03-22
HUP0200709A3 (en) 2004-07-28
CN1149209C (zh) 2004-05-12
BR0007500A (pt) 2001-10-23
CZ20012550A3 (cs) 2002-02-13
KR100775720B1 (ko) 2007-11-09
CN1347414A (zh) 2002-05-01
NO20013444D0 (no) 2001-07-11
KR20010086471A (ko) 2001-09-12
WO2000042037A1 (de) 2000-07-20
IL144136A (en) 2006-12-10
KR100687682B1 (ko) 2007-02-28
NO20013443D0 (no) 2001-07-11
CN1345319A (zh) 2002-04-17
TWI274750B (en) 2007-03-01
PL350246A1 (en) 2002-12-02
AU772948B2 (en) 2004-05-13
CA2359942A1 (en) 2000-07-20
CN1267430C (zh) 2006-08-02
CN1345318A (zh) 2002-04-17
AR022228A1 (es) 2002-09-04
PL200238B1 (pl) 2008-12-31
TR200102025T2 (tr) 2002-05-21
AR022229A1 (es) 2002-09-04
PL349841A1 (en) 2002-09-23
JP2002534521A (ja) 2002-10-15
EP1144405A1 (de) 2001-10-17
AU2436700A (en) 2000-08-01
PL201889B1 (pl) 2009-05-29
EP1144405B1 (de) 2009-11-25
CA2359948A1 (en) 2000-07-20
TR200102026T2 (tr) 2001-12-21
JP2002534520A (ja) 2002-10-15
KR100730667B1 (ko) 2007-06-21
BG105783A (en) 2002-03-29
BG65105B1 (bg) 2007-02-28
IL144137A0 (en) 2002-05-23
DE50015576D1 (de) 2009-04-16
JP4933694B2 (ja) 2012-05-16
ZA200106584B (en) 2002-08-12
AU773047B2 (en) 2004-05-13
WO2000042038A1 (de) 2000-07-20
ES2288839T3 (es) 2008-02-01
SK9862001A3 (en) 2002-04-04
US6579892B1 (en) 2003-06-17
BR0007504A (pt) 2001-10-02
CZ303926B6 (cs) 2013-06-26
HK1045311B (zh) 2007-03-30
NZ512864A (en) 2003-04-29
DE50015802D1 (de) 2010-01-07
EP1140908B1 (de) 2009-03-04
ZA200106585B (en) 2002-08-12
AR022230A1 (es) 2002-09-04
AU2289700A (en) 2000-08-01
ES2334326T3 (es) 2010-03-09
CO5150227A1 (es) 2002-04-29
AU2541200A (en) 2000-08-01
CA2359952A1 (en) 2000-07-20
ID29552A (id) 2001-09-06
CO5150224A1 (es) 2002-04-29
JP2002534519A (ja) 2002-10-15
EP1140908A1 (de) 2001-10-10
US6583166B1 (en) 2003-06-24
HK1045311A1 (en) 2002-11-22
HUP0200709A2 (hu) 2002-07-29
US6602867B1 (en) 2003-08-05
KR20010086470A (ko) 2001-09-12
ID29930A (id) 2001-10-25
HUP0200522A2 (en) 2002-06-29
CO5150182A1 (es) 2002-04-29
NO20013444L (no) 2001-07-11
JP4615125B2 (ja) 2011-01-19
DE50014472D1 (de) 2007-08-23
NZ512830A (en) 2003-08-29
ATE366729T1 (de) 2007-08-15
NO20013443L (no) 2001-07-12
SK9852001A3 (en) 2002-04-04
BG65086B1 (bg) 2007-02-28
IL144136A0 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
HRP20010590A2 (en) Triazole compounds and their use
DE60132235T2 (de) Tetrahydrobenzazepin-derivate zur verwendung als dopamin-d3-rezeptor-modulatoren (antipsychotische mittel)
TW591022B (en) Tetrahydropyridino or piperidino heterocyclic derivatives
CN101511800B (zh) 三唑基苯基苯磺酰胺
TWI406857B (zh) 關於診斷與治療有關蝟狀途徑之病理學疾病的新穎化合物、其醫藥組合物及用途
KR100441073B1 (ko) 치환된아자-및디아자시클로헵탄및시클로옥탄화합물및그의용도
HRP20000014A2 (en) Triazole compounds and the use thereof as dopamine-d<->3<p>-ligands
JP2009520740A (ja) スルホキシイミン置換ピリミジン、それらの調製及び医薬としての使用
CA2978823A1 (en) Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
KR20090034339A (ko) 신규한 피리딘 유사체
WO2007042784A2 (en) Pyrimidin-4-yl-3, 4-dihydr0-2h- pyrrolo [1, 2a] pyrazin-1-one compounds
AU2020404956A1 (en) Compounds modulating protein recruitment and/or degradation
WO2004103968A1 (en) Sulfopyrroles
EP1644338A1 (en) 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
WO2008022747A1 (en) Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents
KR101730205B1 (ko) 신규 (헤테로사이클/테트라히드로피리딘)-(피페라지닐)-1-알카논 및 (헤테로사이클/디히드로피롤리딘)-(피페라지닐)-1-알카논유도체, 및 ｐ75 억제제로서의 그의 용도
MXPA01006840A (en) Triazole compounds with dopamine-d3-receptor affinity
MXPA01006816A (en) Triazole compounds with dopamine-d3-receptor affinity

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
OBST Application withdrawn